Rare Disease Drug Comprehensive Study by Application (Hospitals, Clinics, Others), Disease (Oncologic Diseases, Metabolic Diseases, Hematologic & Immunologic Diseases, Infectious Diseases, Neurologic Diseases, Other Rare Diseases), Form (Tablet, Powder, Injections, Others), Distribution Channel (Pharmacies, Grocery Stores, Internet Sales, Mail Order, Direct Marketing Routes, Other Convenience Stores), Indication (Non-Hodgkin Lymphoma, Acute Myeloid Leukemia, Cystic Fibrosis, Glioma, Pancreatic Cancer, Ovarian Cancer, Multiple Myeloma, Duchenne Muscular Dystrophy, Graft vs Host Disease, Renal Cell Carcinoma, Others) Players and Region - Global Market Outlook to 2027

Rare Disease Drug Market by XX Submarkets | Forecast Years 2022-2027  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
The rare diseases drug highly conditions as an orphan drug. It is highly utilized in the United States regions. There are near about 7000 rare diseases across the globe. The highest number of patients related to the rare disease drugs in the United States, the European Union, and Japan. The market is growing at a higher rate because of the increased number of current willingness and the increasing number of industry players. With the growing concern towards rare disease drugs, many emerging economies are focusing on development initiatives. For instance, India is looking to set rare diseases drug policy and also developing domestic treatments. In India increasing the occurrence of Duchenne muscular dystrophy among children forced the Ministry of Health and Family Welfare forming the national Policy for the treatment of rare diseases. Globally, also various legislations are developing in concern of the rare disease drugs such as the United States Orphan Drug Act is initiating various rare disease drug development.This growth is primarily driven by Rising Awareness among Consumers .

AttributesDetails
Study Period2017-2027
Base Year2021
Forecast Period2022-2027
Volume UnitK Units
Value UnitUSD (Million)
Dominating TypePharmacies
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


The Health Care Supplies sector in the region has been increasing at a sustainable rate and further growth is expected to be witnessed over the forecast period, owing to the robust investments and expansion in production facilities in the region. Major Players, such as Novartis (Switzerland), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (United States), Sanofi S.A. (France), Alexion Pharmaceuticals, Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), AstraZeneca (United Kingdom), Eisai Co., Ltd. (Japan) and Daiichi Sankyo Company Limited (Japan), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

Key Developments in the Market:
In Feb 2019, Ipsen announced the acquisition of the Clementia Pharmaceuticals for the treatment of the key late-stage clinical asset palovarotene, multiple osteochondromas, and others. Through this agreement, the company is aiming to enhance its product portfolio in rare diseases across the globe.
In Aug 2019, Critical path Institute and advocacy organization national organization revealed its new data and analytics platform for rare disorders. This platform is having multiple sources including clinical trials, observational studies, real-time data, and others.The global rare disease drug market is highly competitive and consists of some key players. In terms of market share, few of the key players presently dominate the global market. These market players are leveraging on strategic collaborative creativities to intensification their market share and escalation their profitability.

Regulatory Insights:
The rare disease drugs are regulated by the FDA. Recently, in the market there are three new drugs approved by the FDA for the treatment of two new types of rare diseases including non-Hodgkin lymphomas, and Fabry disease. The new drugs are Mogamulizumab-kpkc injection, Lanadelumab-flyo, and migalastat. Recently, the United States regulators registered COVID-19 as rare disease treatment. For this FDA grant an experimental medicine known as remdeivir for the treatment of coronavirus disease. With the continuously rising COVID-19 cases in the United States region, the health agency's made decisions to provide remdesivir at a lower price (if it will be approved).

Influencing Trend:
Increase in investment from the manufacturers of the leading drug across the globe to developing therapies, invest more in research and focused on offering innovative solutions. Which can bring high potential to offer a solution which impacted on rare diseases. The company is providing drugs to provide patients which includes emerging markets, with advance healthcare.

Market Growth Drivers:
Rising Awareness among Consumers, Technology Advancement in Manufacturing Process and Increasing Number of Rare Diseases in North America Regions, it almost occurs in one in ten American

Challenges:
The high challenge for patients, they are facing huge diversity in their clinical histories. These variables include age, disease progression, and various outcomes, whether they are clinician-reported, observer-reported, or patient-reported outcomes.

Restraints:
Fluctuation in Cost of Raw Materials Associated With Rare Disease Drugs and There are around 95 percent of rare disease which do not have any treatment across the globe

Opportunities:
Development in Drug Manufacturing Countries and Rising Investment of Research and Development on the Rare Disease Drugs, in Terms of Inventing New Treatments

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mainly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the market's growth. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Data Sources of Rare Disease Drug Market Study

Primary Collection: InMail, LinkedIn Groups, Survey Monkey, Google, and Other professional Forums are some of the mediums utilized to gather primary data through key industry participants and appointees, subject-matter experts, C-level executives of Rare Disease Drug Industry, among others including independent industry consultants, experts, to obtain and verify critical qualitative commentary and opinion and quantitative statistics, to assess future market prospects.

The primary interviews and data collected as per the below protocols:
• By Designation: C-Level, D-Level, Others
• By Company Type: Tier 1, Tier 2, Tier 3

Secondary Data Sources such as Annual reports, Press releases, Analyst meetings, Conference calls, Investor presentations, Management statements, and SEC filings of Rare Disease Drug players along with Regulatory Sites, Association, World bank, etc were used as sources secondary set of data.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Rare Disease Drug Study Sheds Light on
— The Rare Disease Drug Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Rare Disease Drug industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Rare Disease Drug industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Others
By Disease
  • Oncologic Diseases
  • Metabolic Diseases
  • Hematologic & Immunologic Diseases
  • Infectious Diseases
  • Neurologic Diseases
  • Other Rare Diseases

By Form
  • Tablet
  • Powder
  • Injections
  • Others

By Distribution Channel
  • Pharmacies
  • Grocery Stores
  • Internet Sales
  • Mail Order
  • Direct Marketing Routes
  • Other Convenience Stores

By Indication
  • Non-Hodgkin Lymphoma
  • Acute Myeloid Leukemia
  • Cystic Fibrosis
  • Glioma
  • Pancreatic Cancer
  • Ovarian Cancer
  • Multiple Myeloma
  • Duchenne Muscular Dystrophy
  • Graft vs Host Disease
  • Renal Cell Carcinoma
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Awareness among Consumers
      • 3.2.2. Technology Advancement in Manufacturing Process
      • 3.2.3. Increasing Number of Rare Diseases in North America Regions, it almost occurs in one in ten American
    • 3.3. Market Challenges
      • 3.3.1. The high challenge for patients, they are facing huge diversity in their clinical histories. These variables include age, disease progression, and various outcomes, whether they are clinician-reported, observer-reported, or patient-reported outcomes.
    • 3.4. Market Trends
      • 3.4.1. Increase in investment from the manufacturers of the leading drug across the globe to developing therapies, invest more in research and focused on offering innovative solutions. Which can bring high potential to offer a solution which impacted on rare diseases. The company is providing drugs to provide patients which includes emerging markets, with advance healthcare.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Rare Disease Drug, by Application, Disease, Form, Distribution Channel, Indication and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Rare Disease Drug (Value)
      • 5.2.1. Global Rare Disease Drug by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Others
      • 5.2.2. Global Rare Disease Drug by: Disease (Value)
        • 5.2.2.1. Oncologic Diseases
        • 5.2.2.2. Metabolic Diseases
        • 5.2.2.3. Hematologic & Immunologic Diseases
        • 5.2.2.4. Infectious Diseases
        • 5.2.2.5. Neurologic Diseases
        • 5.2.2.6. Other Rare Diseases
      • 5.2.3. Global Rare Disease Drug by: Form (Value)
        • 5.2.3.1. Tablet
        • 5.2.3.2. Powder
        • 5.2.3.3. Injections
        • 5.2.3.4. Others
      • 5.2.4. Global Rare Disease Drug by: Distribution Channel (Value)
        • 5.2.4.1. Pharmacies
        • 5.2.4.2. Grocery Stores
        • 5.2.4.3. Internet Sales
        • 5.2.4.4. Mail Order
        • 5.2.4.5. Direct Marketing Routes
        • 5.2.4.6. Other Convenience Stores
      • 5.2.5. Global Rare Disease Drug by: Indication (Value)
        • 5.2.5.1. Non-Hodgkin Lymphoma
        • 5.2.5.2. Acute Myeloid Leukemia
        • 5.2.5.3. Cystic Fibrosis
        • 5.2.5.4. Glioma
        • 5.2.5.5. Pancreatic Cancer
        • 5.2.5.6. Ovarian Cancer
        • 5.2.5.7. Multiple Myeloma
        • 5.2.5.8. Duchenne Muscular Dystrophy
        • 5.2.5.9. Graft vs Host Disease
        • 5.2.5.10. Renal Cell Carcinoma
        • 5.2.5.11. Others
      • 5.2.6. Global Rare Disease Drug Region
        • 5.2.6.1. South America
          • 5.2.6.1.1. Brazil
          • 5.2.6.1.2. Argentina
          • 5.2.6.1.3. Rest of South America
        • 5.2.6.2. Asia Pacific
          • 5.2.6.2.1. China
          • 5.2.6.2.2. Japan
          • 5.2.6.2.3. India
          • 5.2.6.2.4. South Korea
          • 5.2.6.2.5. Taiwan
          • 5.2.6.2.6. Australia
          • 5.2.6.2.7. Rest of Asia-Pacific
        • 5.2.6.3. Europe
          • 5.2.6.3.1. Germany
          • 5.2.6.3.2. France
          • 5.2.6.3.3. Italy
          • 5.2.6.3.4. United Kingdom
          • 5.2.6.3.5. Netherlands
          • 5.2.6.3.6. Rest of Europe
        • 5.2.6.4. MEA
          • 5.2.6.4.1. Middle East
          • 5.2.6.4.2. Africa
        • 5.2.6.5. North America
          • 5.2.6.5.1. United States
          • 5.2.6.5.2. Canada
          • 5.2.6.5.3. Mexico
    • 5.3. Global Rare Disease Drug (Price)
  • 6. Rare Disease Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Bristol-Myers Squibb Company (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Celgene Corporation (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. F. Hoffmann-La Roche Ltd. (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer, Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sanofi S.A. (France)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Alexion Pharmaceuticals, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Eli Lilly and Company (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Novo Nordisk A/S (Denmark)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. AstraZeneca (United Kingdom)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Eisai Co., Ltd. (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Daiichi Sankyo Company Limited (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
  • 7. Global Rare Disease Drug Sale, by Application, Disease, Form, Distribution Channel, Indication and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Rare Disease Drug (Value)
      • 7.2.1. Global Rare Disease Drug by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Others
      • 7.2.2. Global Rare Disease Drug by: Disease (Value)
        • 7.2.2.1. Oncologic Diseases
        • 7.2.2.2. Metabolic Diseases
        • 7.2.2.3. Hematologic & Immunologic Diseases
        • 7.2.2.4. Infectious Diseases
        • 7.2.2.5. Neurologic Diseases
        • 7.2.2.6. Other Rare Diseases
      • 7.2.3. Global Rare Disease Drug by: Form (Value)
        • 7.2.3.1. Tablet
        • 7.2.3.2. Powder
        • 7.2.3.3. Injections
        • 7.2.3.4. Others
      • 7.2.4. Global Rare Disease Drug by: Distribution Channel (Value)
        • 7.2.4.1. Pharmacies
        • 7.2.4.2. Grocery Stores
        • 7.2.4.3. Internet Sales
        • 7.2.4.4. Mail Order
        • 7.2.4.5. Direct Marketing Routes
        • 7.2.4.6. Other Convenience Stores
      • 7.2.5. Global Rare Disease Drug by: Indication (Value)
        • 7.2.5.1. Non-Hodgkin Lymphoma
        • 7.2.5.2. Acute Myeloid Leukemia
        • 7.2.5.3. Cystic Fibrosis
        • 7.2.5.4. Glioma
        • 7.2.5.5. Pancreatic Cancer
        • 7.2.5.6. Ovarian Cancer
        • 7.2.5.7. Multiple Myeloma
        • 7.2.5.8. Duchenne Muscular Dystrophy
        • 7.2.5.9. Graft vs Host Disease
        • 7.2.5.10. Renal Cell Carcinoma
        • 7.2.5.11. Others
      • 7.2.6. Global Rare Disease Drug Region
        • 7.2.6.1. South America
          • 7.2.6.1.1. Brazil
          • 7.2.6.1.2. Argentina
          • 7.2.6.1.3. Rest of South America
        • 7.2.6.2. Asia Pacific
          • 7.2.6.2.1. China
          • 7.2.6.2.2. Japan
          • 7.2.6.2.3. India
          • 7.2.6.2.4. South Korea
          • 7.2.6.2.5. Taiwan
          • 7.2.6.2.6. Australia
          • 7.2.6.2.7. Rest of Asia-Pacific
        • 7.2.6.3. Europe
          • 7.2.6.3.1. Germany
          • 7.2.6.3.2. France
          • 7.2.6.3.3. Italy
          • 7.2.6.3.4. United Kingdom
          • 7.2.6.3.5. Netherlands
          • 7.2.6.3.6. Rest of Europe
        • 7.2.6.4. MEA
          • 7.2.6.4.1. Middle East
          • 7.2.6.4.2. Africa
        • 7.2.6.5. North America
          • 7.2.6.5.1. United States
          • 7.2.6.5.2. Canada
          • 7.2.6.5.3. Mexico
    • 7.3. Global Rare Disease Drug (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Rare Disease Drug: by Application(USD Million)
  • Table 2. Rare Disease Drug Hospitals , by Region USD Million (2016-2021)
  • Table 3. Rare Disease Drug Clinics , by Region USD Million (2016-2021)
  • Table 4. Rare Disease Drug Others , by Region USD Million (2016-2021)
  • Table 5. Rare Disease Drug: by Disease(USD Million)
  • Table 6. Rare Disease Drug Oncologic Diseases , by Region USD Million (2016-2021)
  • Table 7. Rare Disease Drug Metabolic Diseases , by Region USD Million (2016-2021)
  • Table 8. Rare Disease Drug Hematologic & Immunologic Diseases , by Region USD Million (2016-2021)
  • Table 9. Rare Disease Drug Infectious Diseases , by Region USD Million (2016-2021)
  • Table 10. Rare Disease Drug Neurologic Diseases , by Region USD Million (2016-2021)
  • Table 11. Rare Disease Drug Other Rare Diseases , by Region USD Million (2016-2021)
  • Table 12. Rare Disease Drug: by Form(USD Million)
  • Table 13. Rare Disease Drug Tablet , by Region USD Million (2016-2021)
  • Table 14. Rare Disease Drug Powder , by Region USD Million (2016-2021)
  • Table 15. Rare Disease Drug Injections , by Region USD Million (2016-2021)
  • Table 16. Rare Disease Drug Others , by Region USD Million (2016-2021)
  • Table 17. Rare Disease Drug: by Distribution Channel(USD Million)
  • Table 18. Rare Disease Drug Pharmacies , by Region USD Million (2016-2021)
  • Table 19. Rare Disease Drug Grocery Stores , by Region USD Million (2016-2021)
  • Table 20. Rare Disease Drug Internet Sales , by Region USD Million (2016-2021)
  • Table 21. Rare Disease Drug Mail Order , by Region USD Million (2016-2021)
  • Table 22. Rare Disease Drug Direct Marketing Routes , by Region USD Million (2016-2021)
  • Table 23. Rare Disease Drug Other Convenience Stores , by Region USD Million (2016-2021)
  • Table 24. Rare Disease Drug: by Indication(USD Million)
  • Table 25. Rare Disease Drug Non-Hodgkin Lymphoma , by Region USD Million (2016-2021)
  • Table 26. Rare Disease Drug Acute Myeloid Leukemia , by Region USD Million (2016-2021)
  • Table 27. Rare Disease Drug Cystic Fibrosis , by Region USD Million (2016-2021)
  • Table 28. Rare Disease Drug Glioma , by Region USD Million (2016-2021)
  • Table 29. Rare Disease Drug Pancreatic Cancer , by Region USD Million (2016-2021)
  • Table 30. Rare Disease Drug Ovarian Cancer , by Region USD Million (2016-2021)
  • Table 31. Rare Disease Drug Multiple Myeloma , by Region USD Million (2016-2021)
  • Table 32. Rare Disease Drug Duchenne Muscular Dystrophy , by Region USD Million (2016-2021)
  • Table 33. Rare Disease Drug Graft vs Host Disease , by Region USD Million (2016-2021)
  • Table 34. Rare Disease Drug Renal Cell Carcinoma , by Region USD Million (2016-2021)
  • Table 35. Rare Disease Drug Others , by Region USD Million (2016-2021)
  • Table 36. South America Rare Disease Drug, by Country USD Million (2016-2021)
  • Table 37. South America Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 38. South America Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 39. South America Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 40. South America Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 41. South America Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 42. Brazil Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 43. Brazil Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 44. Brazil Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 45. Brazil Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 46. Brazil Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 47. Argentina Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 48. Argentina Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 49. Argentina Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 50. Argentina Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 51. Argentina Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 52. Rest of South America Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 53. Rest of South America Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 54. Rest of South America Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 55. Rest of South America Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 56. Rest of South America Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 57. Asia Pacific Rare Disease Drug, by Country USD Million (2016-2021)
  • Table 58. Asia Pacific Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 59. Asia Pacific Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 60. Asia Pacific Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 61. Asia Pacific Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 62. Asia Pacific Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 63. China Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 64. China Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 65. China Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 66. China Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 67. China Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 68. Japan Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 69. Japan Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 70. Japan Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 71. Japan Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 72. Japan Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 73. India Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 74. India Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 75. India Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 76. India Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 77. India Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 78. South Korea Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 79. South Korea Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 80. South Korea Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 81. South Korea Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 82. South Korea Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 83. Taiwan Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 84. Taiwan Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 85. Taiwan Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 86. Taiwan Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 87. Taiwan Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 88. Australia Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 89. Australia Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 90. Australia Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 91. Australia Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 92. Australia Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 93. Rest of Asia-Pacific Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 94. Rest of Asia-Pacific Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 95. Rest of Asia-Pacific Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 96. Rest of Asia-Pacific Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 97. Rest of Asia-Pacific Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 98. Europe Rare Disease Drug, by Country USD Million (2016-2021)
  • Table 99. Europe Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 100. Europe Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 101. Europe Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 102. Europe Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 103. Europe Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 104. Germany Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 105. Germany Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 106. Germany Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 107. Germany Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 108. Germany Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 109. France Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 110. France Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 111. France Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 112. France Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 113. France Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 114. Italy Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 115. Italy Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 116. Italy Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 117. Italy Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 118. Italy Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 119. United Kingdom Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 120. United Kingdom Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 121. United Kingdom Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 122. United Kingdom Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 123. United Kingdom Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 124. Netherlands Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 125. Netherlands Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 126. Netherlands Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 127. Netherlands Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 128. Netherlands Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 129. Rest of Europe Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 130. Rest of Europe Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 131. Rest of Europe Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 132. Rest of Europe Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 133. Rest of Europe Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 134. MEA Rare Disease Drug, by Country USD Million (2016-2021)
  • Table 135. MEA Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 136. MEA Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 137. MEA Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 138. MEA Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 139. MEA Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 140. Middle East Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 141. Middle East Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 142. Middle East Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 143. Middle East Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 144. Middle East Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 145. Africa Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 146. Africa Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 147. Africa Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 148. Africa Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 149. Africa Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 150. North America Rare Disease Drug, by Country USD Million (2016-2021)
  • Table 151. North America Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 152. North America Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 153. North America Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 154. North America Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 155. North America Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 156. United States Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 157. United States Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 158. United States Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 159. United States Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 160. United States Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 161. Canada Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 162. Canada Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 163. Canada Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 164. Canada Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 165. Canada Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 166. Mexico Rare Disease Drug, by Application USD Million (2016-2021)
  • Table 167. Mexico Rare Disease Drug, by Disease USD Million (2016-2021)
  • Table 168. Mexico Rare Disease Drug, by Form USD Million (2016-2021)
  • Table 169. Mexico Rare Disease Drug, by Distribution Channel USD Million (2016-2021)
  • Table 170. Mexico Rare Disease Drug, by Indication USD Million (2016-2021)
  • Table 171. Company Basic Information, Sales Area and Its Competitors
  • Table 172. Company Basic Information, Sales Area and Its Competitors
  • Table 173. Company Basic Information, Sales Area and Its Competitors
  • Table 174. Company Basic Information, Sales Area and Its Competitors
  • Table 175. Company Basic Information, Sales Area and Its Competitors
  • Table 176. Company Basic Information, Sales Area and Its Competitors
  • Table 177. Company Basic Information, Sales Area and Its Competitors
  • Table 178. Company Basic Information, Sales Area and Its Competitors
  • Table 179. Company Basic Information, Sales Area and Its Competitors
  • Table 180. Company Basic Information, Sales Area and Its Competitors
  • Table 181. Company Basic Information, Sales Area and Its Competitors
  • Table 182. Company Basic Information, Sales Area and Its Competitors
  • Table 183. Rare Disease Drug: by Application(USD Million)
  • Table 184. Rare Disease Drug Hospitals , by Region USD Million (2022-2027)
  • Table 185. Rare Disease Drug Clinics , by Region USD Million (2022-2027)
  • Table 186. Rare Disease Drug Others , by Region USD Million (2022-2027)
  • Table 187. Rare Disease Drug: by Disease(USD Million)
  • Table 188. Rare Disease Drug Oncologic Diseases , by Region USD Million (2022-2027)
  • Table 189. Rare Disease Drug Metabolic Diseases , by Region USD Million (2022-2027)
  • Table 190. Rare Disease Drug Hematologic & Immunologic Diseases , by Region USD Million (2022-2027)
  • Table 191. Rare Disease Drug Infectious Diseases , by Region USD Million (2022-2027)
  • Table 192. Rare Disease Drug Neurologic Diseases , by Region USD Million (2022-2027)
  • Table 193. Rare Disease Drug Other Rare Diseases , by Region USD Million (2022-2027)
  • Table 194. Rare Disease Drug: by Form(USD Million)
  • Table 195. Rare Disease Drug Tablet , by Region USD Million (2022-2027)
  • Table 196. Rare Disease Drug Powder , by Region USD Million (2022-2027)
  • Table 197. Rare Disease Drug Injections , by Region USD Million (2022-2027)
  • Table 198. Rare Disease Drug Others , by Region USD Million (2022-2027)
  • Table 199. Rare Disease Drug: by Distribution Channel(USD Million)
  • Table 200. Rare Disease Drug Pharmacies , by Region USD Million (2022-2027)
  • Table 201. Rare Disease Drug Grocery Stores , by Region USD Million (2022-2027)
  • Table 202. Rare Disease Drug Internet Sales , by Region USD Million (2022-2027)
  • Table 203. Rare Disease Drug Mail Order , by Region USD Million (2022-2027)
  • Table 204. Rare Disease Drug Direct Marketing Routes , by Region USD Million (2022-2027)
  • Table 205. Rare Disease Drug Other Convenience Stores , by Region USD Million (2022-2027)
  • Table 206. Rare Disease Drug: by Indication(USD Million)
  • Table 207. Rare Disease Drug Non-Hodgkin Lymphoma , by Region USD Million (2022-2027)
  • Table 208. Rare Disease Drug Acute Myeloid Leukemia , by Region USD Million (2022-2027)
  • Table 209. Rare Disease Drug Cystic Fibrosis , by Region USD Million (2022-2027)
  • Table 210. Rare Disease Drug Glioma , by Region USD Million (2022-2027)
  • Table 211. Rare Disease Drug Pancreatic Cancer , by Region USD Million (2022-2027)
  • Table 212. Rare Disease Drug Ovarian Cancer , by Region USD Million (2022-2027)
  • Table 213. Rare Disease Drug Multiple Myeloma , by Region USD Million (2022-2027)
  • Table 214. Rare Disease Drug Duchenne Muscular Dystrophy , by Region USD Million (2022-2027)
  • Table 215. Rare Disease Drug Graft vs Host Disease , by Region USD Million (2022-2027)
  • Table 216. Rare Disease Drug Renal Cell Carcinoma , by Region USD Million (2022-2027)
  • Table 217. Rare Disease Drug Others , by Region USD Million (2022-2027)
  • Table 218. South America Rare Disease Drug, by Country USD Million (2022-2027)
  • Table 219. South America Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 220. South America Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 221. South America Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 222. South America Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 223. South America Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 224. Brazil Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 225. Brazil Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 226. Brazil Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 227. Brazil Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 228. Brazil Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 229. Argentina Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 230. Argentina Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 231. Argentina Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 232. Argentina Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 233. Argentina Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 234. Rest of South America Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 235. Rest of South America Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 236. Rest of South America Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 237. Rest of South America Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 238. Rest of South America Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 239. Asia Pacific Rare Disease Drug, by Country USD Million (2022-2027)
  • Table 240. Asia Pacific Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 241. Asia Pacific Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 242. Asia Pacific Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 243. Asia Pacific Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 244. Asia Pacific Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 245. China Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 246. China Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 247. China Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 248. China Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 249. China Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 250. Japan Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 251. Japan Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 252. Japan Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 253. Japan Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 254. Japan Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 255. India Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 256. India Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 257. India Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 258. India Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 259. India Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 260. South Korea Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 261. South Korea Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 262. South Korea Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 263. South Korea Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 264. South Korea Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 265. Taiwan Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 266. Taiwan Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 267. Taiwan Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 268. Taiwan Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 269. Taiwan Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 270. Australia Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 271. Australia Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 272. Australia Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 273. Australia Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 274. Australia Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 275. Rest of Asia-Pacific Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 276. Rest of Asia-Pacific Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 277. Rest of Asia-Pacific Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 278. Rest of Asia-Pacific Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 279. Rest of Asia-Pacific Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 280. Europe Rare Disease Drug, by Country USD Million (2022-2027)
  • Table 281. Europe Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 282. Europe Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 283. Europe Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 284. Europe Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 285. Europe Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 286. Germany Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 287. Germany Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 288. Germany Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 289. Germany Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 290. Germany Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 291. France Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 292. France Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 293. France Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 294. France Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 295. France Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 296. Italy Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 297. Italy Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 298. Italy Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 299. Italy Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 300. Italy Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 301. United Kingdom Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 302. United Kingdom Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 303. United Kingdom Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 304. United Kingdom Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 305. United Kingdom Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 306. Netherlands Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 307. Netherlands Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 308. Netherlands Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 309. Netherlands Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 310. Netherlands Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 311. Rest of Europe Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 312. Rest of Europe Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 313. Rest of Europe Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 314. Rest of Europe Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 315. Rest of Europe Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 316. MEA Rare Disease Drug, by Country USD Million (2022-2027)
  • Table 317. MEA Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 318. MEA Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 319. MEA Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 320. MEA Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 321. MEA Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 322. Middle East Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 323. Middle East Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 324. Middle East Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 325. Middle East Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 326. Middle East Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 327. Africa Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 328. Africa Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 329. Africa Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 330. Africa Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 331. Africa Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 332. North America Rare Disease Drug, by Country USD Million (2022-2027)
  • Table 333. North America Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 334. North America Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 335. North America Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 336. North America Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 337. North America Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 338. United States Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 339. United States Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 340. United States Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 341. United States Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 342. United States Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 343. Canada Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 344. Canada Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 345. Canada Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 346. Canada Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 347. Canada Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 348. Mexico Rare Disease Drug, by Application USD Million (2022-2027)
  • Table 349. Mexico Rare Disease Drug, by Disease USD Million (2022-2027)
  • Table 350. Mexico Rare Disease Drug, by Form USD Million (2022-2027)
  • Table 351. Mexico Rare Disease Drug, by Distribution Channel USD Million (2022-2027)
  • Table 352. Mexico Rare Disease Drug, by Indication USD Million (2022-2027)
  • Table 353. Research Programs/Design for This Report
  • Table 354. Key Data Information from Secondary Sources
  • Table 355. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Rare Disease Drug: by Application USD Million (2016-2021)
  • Figure 5. Global Rare Disease Drug: by Disease USD Million (2016-2021)
  • Figure 6. Global Rare Disease Drug: by Form USD Million (2016-2021)
  • Figure 7. Global Rare Disease Drug: by Distribution Channel USD Million (2016-2021)
  • Figure 8. Global Rare Disease Drug: by Indication USD Million (2016-2021)
  • Figure 9. South America Rare Disease Drug Share (%), by Country
  • Figure 10. Asia Pacific Rare Disease Drug Share (%), by Country
  • Figure 11. Europe Rare Disease Drug Share (%), by Country
  • Figure 12. MEA Rare Disease Drug Share (%), by Country
  • Figure 13. North America Rare Disease Drug Share (%), by Country
  • Figure 14. Global Rare Disease Drug share by Players 2021 (%)
  • Figure 15. Global Rare Disease Drug share by Players (Top 3) 2021(%)
  • Figure 16. Global Rare Disease Drug share by Players (Top 5) 2021(%)
  • Figure 17. BCG Matrix for key Companies
  • Figure 18. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 19. Novartis (Switzerland) Revenue: by Geography 2021
  • Figure 20. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 21. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2021
  • Figure 22. Celgene Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 23. Celgene Corporation (United States) Revenue: by Geography 2021
  • Figure 24. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue, Net Income and Gross profit
  • Figure 25. F. Hoffmann-La Roche Ltd. (Switzerland) Revenue: by Geography 2021
  • Figure 26. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer, Inc. (United States) Revenue: by Geography 2021
  • Figure 28. Sanofi S.A. (France) Revenue, Net Income and Gross profit
  • Figure 29. Sanofi S.A. (France) Revenue: by Geography 2021
  • Figure 30. Alexion Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 31. Alexion Pharmaceuticals, Inc. (United States) Revenue: by Geography 2021
  • Figure 32. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 33. Eli Lilly and Company (United States) Revenue: by Geography 2021
  • Figure 34. Novo Nordisk A/S (Denmark) Revenue, Net Income and Gross profit
  • Figure 35. Novo Nordisk A/S (Denmark) Revenue: by Geography 2021
  • Figure 36. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 37. AstraZeneca (United Kingdom) Revenue: by Geography 2021
  • Figure 38. Eisai Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 39. Eisai Co., Ltd. (Japan) Revenue: by Geography 2021
  • Figure 40. Daiichi Sankyo Company Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 41. Daiichi Sankyo Company Limited (Japan) Revenue: by Geography 2021
  • Figure 42. Global Rare Disease Drug: by Application USD Million (2022-2027)
  • Figure 43. Global Rare Disease Drug: by Disease USD Million (2022-2027)
  • Figure 44. Global Rare Disease Drug: by Form USD Million (2022-2027)
  • Figure 45. Global Rare Disease Drug: by Distribution Channel USD Million (2022-2027)
  • Figure 46. Global Rare Disease Drug: by Indication USD Million (2022-2027)
  • Figure 47. South America Rare Disease Drug Share (%), by Country
  • Figure 48. Asia Pacific Rare Disease Drug Share (%), by Country
  • Figure 49. Europe Rare Disease Drug Share (%), by Country
  • Figure 50. MEA Rare Disease Drug Share (%), by Country
  • Figure 51. North America Rare Disease Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis (Switzerland)
  • Bristol-Myers Squibb Company (United States)
  • Celgene Corporation (United States)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Pfizer, Inc. (United States)
  • Sanofi S.A. (France)
  • Alexion Pharmaceuticals, Inc. (United States)
  • Eli Lilly and Company (United States)
  • Novo Nordisk A/S (Denmark)
  • AstraZeneca (United Kingdom)
  • Eisai Co., Ltd. (Japan)
  • Daiichi Sankyo Company Limited (Japan)
Additional players considered in the study are as follows:
Bayer AG (Germany) , GlaxoSmithKline (United Kingdom) , Merck & Co., Inc. (United States) , Johnson & Johnson (United States) , Biogen, Inc. (United States)
Select User Access Type

Key Highlights of Report


Feb 2023 244 Pages 72 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2017-2021; Base year: 2021; Forecast period: 2022 to 2027
Companies that are profiled in Global Rare Disease Drug Market are Novartis (Switzerland), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), F. Hoffmann-La Roche Ltd. (Switzerland), Pfizer, Inc. (United States), Sanofi S.A. (France), Alexion Pharmaceuticals, Inc. (United States), Eli Lilly and Company (United States), Novo Nordisk A/S (Denmark), AstraZeneca (United Kingdom), Eisai Co., Ltd. (Japan) and Daiichi Sankyo Company Limited (Japan) etc.
Hospitals segment in Global market to hold robust market share owing to "Rising Awareness among Consumers ".
AMA Research predicts that United States Players will contribute to the maximum growth of Global Rare Disease Drug market throughout the forecasted period.
Hospitals dominated the Rare Disease Drug market. This is attributable due to "Rising Awareness among Consumers "

Know More About Global Rare Disease Drug Report?